system to strike a balance between efficient use of and equal access to the deceased organs for deceased donor transplantation. 2 In the United States, only ≈15% of ESRD patients were waitlisted for kidney transplantation, and ≈19 000 patients received a transplant in 2016 among the 103 114 people currently on the waitlist. 3, 4 Despite policy regulations of the Department of Health and Human Services that require organs to be allocated equitably, 5 there are racial and ethnic disparities at each step of the kidney transplant process. Black patients are less likely to be referred for transplant, 6 complete the evaluation process if referred, 7 be placed on the waiting list, 7, 8 and receive a transplant [9] [10] [11] [12] [13] [14] [15] [16] compared to white patients.
In addition, Hispanics have historically had lower transplant rates after waitlisting. 17 Disparities are the result of many potential factors, such as poverty, [18] [19] [20] geography, 8, 20, 21 limited education about transplant, 15, 22 physician bias, 23 and other system-level factors, such as federal policies that guide US organ allocation.
24,25
The new kidney allocation system (KAS) 26 was implemented by the United Network for Organ Sharing (UNOS) in December 2014 in part to improve equity related to dialysis time, and to the group of patients with high panel-reactive antibody. 27 More specifically, changes that were likely to benefit minority patients include the change in the calculation of waiting time, which now starts at dialysis start instead of waitlist, and prioritization of the most sensitized patients, who are disproportionately more likely to be minorities. Changes in allocation priority were intended to improve kidney allocation disparities among different races/ethnicities on the waiting list. 28 Prior to KAS implementation, simulations predicted that black vs white racial disparities in transplantation among patients already on the transplant waiting list would decrease by 6% within 1 year. 3, 29 Subsequent research has confirmed these hypotheses, where racial/ethnic disparities in deceased-donor transplant among waitlisted patients have been at least temporarily eliminated. 30, 31 However, it is unknown how the new KAS policy may have influenced access to the waiting list. It is possible that the implementation of KAS led to increased referrals for transplant evaluation and higher waitlisting, particularly among patients who spent a longer time on dialysis and who were not previously referred or waitlisted for transplant. Because minorities tend to spend longer on dialysis prior to referral for transplantation, 32 the policy change may have differential effects by racial/ethnic group. However, it is also possible that the policy has reduced the sense of urgency to refer some patients who may have only recently started dialysis. Delayed referral to transplant for minority patients could further exacerbate the racial/ethnic disparities in living donor transplantation, which is the optimal treatment for ESRD patients. 33 Thus, the influence of KAS on waitlisting and waitlisting disparities may differ between the incident and prevalent ESRD populations.
The aims of this study were (1) to assess the impact of the 2014 KAS policy change on waitlisting overall, and (2) to evaluate whether racial/ethnic disparities in waitlisting in the United States changed following the policy's implementation. We performed 2 types of analyses to achieve these aims: (1) a time-to-event analysis to examine how KAS affected time from dialysis start to waitlisting among the incident ESRD population, and (2) a trend analysis to examine how the new KAS policy affected monthly waitlisting rates among prevalent (existing) dialysis patients not already on the waiting list.
| MATERIAL S AND ME THODS

| Data sources
To address both study aims, we constructed both an incident and a prevalent (ie, patients already on dialysis) ESRD patient cohort using the United States Renal Data System (USRDS) (Figure 1 ). Because USRDS data do not contain detailed information about active and inactive status of incident waitlisting, we also examined UNOS system data. 34 The incident study population included a retrospective lon- 
| Study variables
In the incident ESRD population, the main study outcome (event)
was placement on the national deceased donor waiting list (ie, waitlisting) overall, including both active and inactive waitlisting, and the secondary outcome was the racial/ethnic disparity in waitlisting after the KAS policy. Outcomes were obtained from USRDS standard analytic files, which are administratively linked with United
Network for Organ Sharing data on waitlisting and transplantation.
The main exposure variables were policy era (pre-and post-KAS; defined above) and race/ethnicity. We defined 5 racial and ethnic groups: white (non-Hispanic), black (non-Hispanic), Hispanic, Asian, and other (including American Indian/Alaska native and Native
Hawaiian/other Pacific Islander).
Among incident ESRD patients, we examined information col- 
| Statistical analyses
In the incident ESRD cohort, we compared demographic and clinical characteristics before and after KAS using χ 2 tests for categori- Table 1 ) in multivariable models; 254 189 (20%) observations had at least 1 covariate imputed.
In the prevalent patient cohort, we examined the monthly count of new waitlisting events and the monthly incidence rate of new waitlisting events among the study population from 2005 to 2015.
We used interrupted time-series models 37 Results from the interrupted time series model were sensitive to the length of pre-intervention periods included for modeling. The length of this period should be neither too short, which may not reflect the long-term trend, nor too long, which may mask the relevant preintervention trend. 37 We selected 
| Sensitivity analyses
Since the implementation of KAS may have had a differential effect on patients who received a living donor transplant after waitlisting,
we performed a sensitivity analysis excluding patients who received a living donor transplant within 180 days of waitlisting (N = 17 845; 9.6%) and excluding those who died within 30 days after dialysis began (N = 31 160; 2.48%), since these patients are less likely eligible for transplantation. 16.6% vs post-KAS: 21.4%) increased after KAS implementation (Table S1 ; all P < .001).
| RE SULTS
| Waitlisting among incident ESRD patients
After adjusting for potential confounders (Table 2) patients. A race/ethnicity and KAS era interaction was significant (P < .0001).
| Change in racial/ethnic disparity in waitlisting among incident ESRD patients
Prior to KAS, the rate of waitlisting was 19% lower among black vs white patients (HR: 0.81; 95% CI, 0.80-0.82). Following KAS, the racial difference declined (P < .001) to 12% (HR: 0.88; 95% CI, 0.85-0.90). The rate of waitlisting for Hispanics (vs whites) was 7% higher (HR: 1.07; 95% CI, 1.06-1.09) pre-KAS and 8% higher post-KAS (HR:
1.08; 95% CI, 1.04-1.12); this difference was not significant (P = .62).
The HR comparing waitlisting among Asian patients with whites was 1.20 (95% CI, 1.18-1.22) pre-KAS, and 1.23 (95% CI, 1.17-1.30) post-KAS, but this difference was not significant (P = .27) ( Table 2 ).
| Waitlisting among prevalent dialysis patients
The number of prevalent dialysis patients who had not been waitlisted increased from 300 990 (45% white, 33% black, 13% Hispanic, and 4% Asian) in January 2005 to 450 027 (43% white, 31% black, 16% Hispanic, and 5% Asian) in December 2015 (Figure 2 ). On average, the monthly rate of waitlisting was 55.0 per 10 000 prevalent ESRD patients (57.1/10 000 for white, 46.7/10 000 for black, 62.0/10 000 for Hispanic, and 80.6/10 000 for Asian patients; P < .001) in the pre-KAS era. In the post-KAS era, monthly waitlisting rates declined to 46.1/10 000 (48.9/10 000 for white, 38.4/10 000 for black, 46.4/10 000 for Hispanic, and 66.4/10 000 for Asian patients; P < .001), respectively.
After adjusting for time trends in the interrupted time-series
analyses, the monthly count of new waitlisting events decreased by 146 events (95% CI, 41-250; P < .001) from the pre-to post-KAS eras ( Figure S2 , Table S3 ). The monthly waitlisting rate also decreased by 3.45/10 000 (95% CI, 0.9-6.0) prevalent ESRD patients overall (P < .001), including 3.57/10 000 for whites (95% CI, 0.62-6.51; P = .017), 3.50/10 000 for blacks (95% CI, 0. 
TA B L E 1 (Contiued)
the pre-to post-KAS eras (Table S3 ). Shorter dialysis vintage was associated with greater decreases in waitlisting post-vs pre-KAS, and declined in a stepwise manner (P < .001). For example, the average adjusted monthly waitlisting rate among prevalent patients whose dialysis vintage was >5 years was similar before and after KAS (−0.51/10 000; 95% CI: −1.98, 0.95) but among patients with <1 year on dialysis, rates were significantly lower than those prior to KAS (−8.59/10 000; 95% CI, −14.95, −2.23) (Figure 3 ).
| Active vs inactive waitlisting
A total of 277 554 (90.7% for pre-KAS and 9.3% for post-KAS) firsttime adult waitlisting events were reported in UNOS data from 2005 to 2015. The proportion of new actively waitlisted patients in the pre-KAS era was 72.1% (72.3% for white, 71.3% for black, 72.2% for Hispanics, and 72.7 for Asian, P < .001), and this increased to 73.5%
post-KAS (71.4% for white, 76.3% for black, 78.0% for Hispanics, and 73.5 for Asian, P < .001). Active waitlisting counts were similar pre-and post-KAS (Figure 4 ; P = .601). Inactive waitlisting counts were significantly lower post-vs pre-KAS ( Figure 5 , P < .001), and there was a greater decline in inactive waitlisting counts among black and Hispanic patients (P < .0001).
| Sensitivity analysis
In the sensitivity analyses excluding the 1.4% of patients who had a living donor transplant within 180 days after waitlisting, the sensitivity analyses excluding patients with a history of cancer (N = 120 635, 9.6%), and the sensitivity analysis excluding patients who died within 30 days after dialysis began (N = 31 160; 2.48%), results were similar to main analyses (Table S2 ).
| D ISCUSS I ON
After the implementation of a major change in the national KAS in
December 2014, the rate of waitlisting declined among both incident and prevalent dialysis patients. There was a 9% decline in overall waitlisting among incident ESRD patients, including an 11% decline among whites, a 10% decline among Hispanics, an 8% decline among The variables included in the time-dependent Cox model included race/ethnicity, age at ESRD start, sex, cause of ESRD, BMI, tobacco use, cancer, congestive heart failure, atherosclerotic heart disease, cerebrovascular disease, peripheral vascular disease, hypertension, diabetes, chronic obstructive pulmonary disease, whether or not a patient had been informed of kidney transplant options, type of health insurance, whether or not a patient had pre-ESRD nephrology care and patient neighborhood (ZIP Code) poverty. Missing values (details in Table 1) were imputed using the median of each variable. A total of 254 189 (20%) of observations in model that had at least 1 covariate imputed. The P value for the black vs white racial/ethnic disparity reduction between pre-KAS and post-KAS periods: P < .001. The P value for the Hispanic vs white racial/ethnic disparity reduction between pre-KAS and post-KAS periods: P = .62. d The P value for the Asian vs white racial/ethnic disparity reduction between pre-KAS and post-KAS periods: P = .27.
with prevalent ESRD, black patients accounted for a larger proportion of prevalent patients with long dialysis times who were yet to be waitlisted or waitlisted long after starting renal replacement therapy and thus had a higher chance of transplantation under the new KAS policy prioritization. For incident patients, the new allocation system reduces the urgency for transplant centers to waitlist incident dialysis patients, and this may disproportionately impact white patients who have traditionally been more likely to be waitlisted soon after starting dialysis. Our data suggest that there was a larger increase in the proportion of minority patients actively waitlisted post-KAS, which may partially explain these findings. Moreover, education and pre-ESRD nephrology care as reported on the CMS-2728 form im- factors for both groups would be expected to decrease the waitlisting disparity, because the disparity was assessed as a ratio (a HR) in this analysis rather than a difference. It also may be that a per-unit increase in these factors is stronger at lower levels, leading to a greater increase in waitlisting among blacks compared with whites.
In other groupwise comparisons, we found that waitlisting for
Hispanics was higher than for whites both before and after KAS. These results are similar to previous findings showing no ethnic disparities in waitlisting, but lower rates of transplantation among Hispanics once waitlisted. 17, 32 In our study, Hispanics had a higher overall incidence of waitlisting but a slower time to waitlisting than white patients. Other analyses 30 have also reported that KAS increased transplant rates for
Hispanics after waitlisting, thus reducing the overall ethnic disparity in transplant access. We also report that waitlisting for Asian patients decreased after KAS, but this group still had the highest waitlisting rate among all racial/ethnic groups, as previously reported. 3 Importantly, This study has limitations. First, the study has only ≈1 year of follow-up data after KAS implementation, which is the most recent data available from USRDS. The other major national kidney registry, UNOS, has more recent data on waitlisting events, but does not take into account the changing denominator population of incident or prevalent dialysis patients prior to waitlisting. In addition, the decline in waitlisting for ESRD patients has been further confirmed by the recent release of the national USRDS report. 43 Additional follow-up data are needed to confirm longer-term effects of the policy.
Second, the national surveillance data used for the study did not have contextual information such as dialysis facility staff perspectives on the impact of the policy on their referral patterns, transplant center waitlisting policies, and patient perspectives. These data also do not contain information on which patients were eligible for transplantation. Our study thus assumes there was no racial/ethnic difference in transplant eligibility from pre-to post-KAS. Third, we were unable to assess the impact of the policy on smaller racial/ethnic groups, as the "other" category of patients was too small and heterogeneous to make meaningful conclusions about the policy's impact. Other limitations include missing covariate data and the potential for residual con- Our study also has several strengths. The study population was large and diverse and examines the impact of a major policy change for both incident and prevalent ESRD patients. Results are generalizable to all treated US ESRD patients, as USRDS is a nearcomplete representation of these patients. Second, follow-up data on outcomes of waitlisting are nearly complete, so validity is unlikely to be threatened by selection bias. Third, availability of individuallevel follow-up data allowed for estimation of individual-level time to waitlisting and its potential variation by important sociodemographic factors.
Overall, the likelihood of waitlisting for all racial/ethnic groups significantly declined after the new national KAS, and this was primarily due to declines in inactive waitlisting and waitlisting among those with lower time on dialysis. Racial disparities in waitlisting for kidney transplantation were reduced between black and white ESRD patients after the implementation of KAS in December 2014 in part to a steeper decline in inactive waitlisting among minorities and a greater proportion of actively waitlisted minority patients; however, black vs white disparities in waitlisting remain.
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